Nov 15, 2017   SOURCE: PR NewsWire

Global Ophthalmic Drugs Market Expected to Reach $42,663 Million by 2023 - Allied Market Research

PORTLAND, Oregon and PUNE, India, November 15, 2017 /PRNewswire/ --

According to a new report published by Allied Market Research, titled, "Ophthalmic Drugs Market by Indication, Type, Distribution Channel, Dosage Form, Technology, and Therapeutic Class: Global Opportunity Analysis and Industry Forecast, 2017-2023 [https://www.alliedmarketresearch.com/ophthalmic-drugs-market ]," the global ophthalmic drugs market was valued at $29,613 million in 2016, and is projected to reach $42,663 million by 2023, growing at a CAGR of 5.3% from 2017 to 2023. The retinal disorders segment accounted for 26.6% of the global ophthalmic drugs market in 2016.

(Logo: http://photos.prnewswire.com/prnh/20140911/647229 )

The development of effective ophthalmic is crucial is the current scenario, owing to increase in incidence of ophthalmic disorders such as glaucoma, cataract, and other common eye infections. Ophthalmic drugs are administered in different dosage forms depending upon the indication. Market players focus on innovation of novel approaches for the development of ophthalmic drugs over the years, including small molecule, biologics, and recombinant technologies, thereby driving the growth of ophthalmic drugs market.

Do Enquiry for Sample Report@ https://www.alliedmarketresearch.com/request-sample/310

Increase in focus towards developing combination therapies for treatment of ophthalmic disorders, prevalence of these disorders, and surge in geriatric population are projected to drive the ophthalmic drugs market growth. In addition, continuous change in demographics worldwide supplements this growth. However, longer timelines required for the approval of novel ophthalmic drugs and side effects associated with the same limit market expansion.

Conversely, surge in investment by manufacturers in the emerging economies and rise in initiatives to reduce the burden of glaucoma globally are anticipated to offer lucrative opportunities for market expansion. The multicompartment drug delivery systems is expected to witness a CAGR of 8.0% from 2017 to 2023, as these systems are ideal to sustain and deliver therapeutics to the target tissues and cells. The anti-inflammatory segment accounted for 28% of ophthalmic drugs market share in 2016, and is projected to continue its dominance throughout the forecast period.

Among distribution channel, hospital pharmacies generated the highest revenue in 2016, accounting for 31% of the total ophthalmic drugs market share, and are anticipated to continue this trend throughout the forecast period. Moreover, online pharmacies segment is expected to witness a high growth rate of 5.8%, owing to increase in trend of online ordering and easy availability of drugs.

Do Enquiry before purchasing Report@ https://www.alliedmarketresearch.com/purchase-enquiry/310

KEY FINDINGS OF THE STUDY 

        
        - The liquid ophthalmic drug forms generated the highest revenue in 2016, and are
          anticipated to continue the same trend, registering a CAGR of 4.1% from 2017 to 2023.
        - The cell therapy technologies registered significant growth rate and is expected to
          register a CAGR of 6.5%.
        - North America dominated the market, accounting for maximum share of 36% of the total
          market in 2016 and is expected to witness a CAGR of 4.4%.
        - The online pharmacies segment is witnessing the highest CAGR of 5.8% among the end
          users.
        - Anti-inflammatory drugs accounted for two-sevenths share of the global ophthalmic
          drugs market in 2016.

Asia-Pacific is expected to witness highest growth rate for ophthalmic drugs throughout the forecast period, and is expected to continue this trend, owing to high population density, increase in geriatric population, and rise in incidence of congenital glaucoma and cataract in India and China.

The key players operating in the ophthalmic drugs market have adopted product launch as one of their key developmental strategies, among others such as business expansion, product development, and business acquisition. The major companies profiled in the report include Santen Pharmaceutical Co., Ltd., Bausch & Lomb Inc. (Valeant Pharmaceuticals International, Inc.), Shire Plc, Alcon (Novartis), Genentech, Inc. Allergan, Plc, Sun Pharmaceutical Industries Limited, Actavis Generics (Teva Pharmaceutical Industries Ltd.), Regeneron Pharmaceuticals, Inc., and Pfizer Inc.

Ask for discount before buying@ https://www.alliedmarketresearch.com/get-discount/310

About Us: Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. 

            Contact: 
        Dhananjay Potle 
        5933 NE Win Sivers Drive 
        #205, Portland, OR 97220 
        United States 
        Toll Free: +1-800-792-5285 
        UK: +44-845-528-1300 
        Hong Kong: +852-301-84916 
        India (Pune): +91-20-66346060 
        Fax: +1   855   550-5975 
        help@alliedmarketresearch.com

Web: https://www.alliedmarketresearch.com 


    Photo: 
    http://photos.prnewswire.com/prnh/20140911/647229

SOURCE Allied Market Research